Trial Profile
Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Switching From Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate to Bictegravir/ Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected Virologically Suppressed Adults
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 16 Dec 2022
Price :
$35
*
At a glance
- Drugs Bictegravir/emtricitabine/tenofovir alafenamide (Primary) ; Efavirenz/emtricitabine/tenofovir-disoproxil-fumarate
- Indications HIV-1 infections
- Focus Adverse reactions
- 15 Aug 2022 Status changed from completed to discontinued.
- 07 May 2021 Status changed from recruiting to completed.
- 27 Sep 2018 Status changed from not yet recruiting to recruiting.